News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cell>Point Completes Phase 2 of Cancer Diagnostic Phase 2/3 Trial
June 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer (NSCLC).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
FDA
Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push
February 17, 2026
·
5 min read
·
Heather McKenzie
Vaccines
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait
February 16, 2026
·
3 min read
·
Annalee Armstrong
Rare diseases
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward
February 12, 2026
·
2 min read
·
Tristan Manalac
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
February 12, 2026
·
1 min read
·
Jennifer Smith-Parker
